Reduluc

Quick links to important sections

Reduluc

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reduluc

Quick Facts: Reduluc (Metformin Hydrochloride)

Property Description
Active ingredient Metformin Hydrochloride
Form Oral Tablet (Immediate and Extended Release)
Pharmacological class Biguanide Antihyperglycemic Agent
General Purpose Long-term blood sugar stabilization
Origin Synthetic, derived from the biguanide structure

What Type of Medicine is Reduluc? (Definition and Classification)

Reduluc is a systemic, prescription-only medication whose active component is the substance Metformin Hydrochloride (INN). The drug is fundamentally utilized to manage persistently elevated blood sugar levels, a typical use scenario in adult metabolic care. It is classified as an antihyperglycemic agent belonging to the biguanide class of oral therapies. This classification is unique because Reduluc is a non-insulin secretagogue, distinguishing it from older classes of glucose-lowering drugs that directly increase insulin release. The biguanide class is utilized for its foundational role in metabolic management.


Composition, Form, and Origin

The medication is composed of the synthetic chemical entity Metformin Hydrochloride combined with the necessary pharmaceutical excipients to create an oral tablet. Reduluc is a brand-name product that delivers the established action of Metformin, which acts as an insulin sensitizer. While the drug’s structure is historically traced to guanidine compounds found in the French lilac, Metformin itself is a purified, synthesized molecule. The medication is designed for convenient administration via the oral route, with the brand commonly available in immediate-release and extended-release formulations, providing flexibility for specific patient protocols.


Reduluc's Role in Managing High Blood Sugar (General Benefit)

The core purpose of Reduluc is to help the body effectively stabilize blood glucose levels over the long term. This goal is achieved by targeting key physiological actions: decreasing the amount of glucose released into the bloodstream by the liver and enhancing the sensitivity of peripheral body tissues to existing insulin. By controlling the body's internal glucose production and optimizing cellular response, Reduluc provides a mechanism for long-term metabolic balance.

What side effects are possible with Reduluc?

Possible Side Effects and Safety Information

The safety profile for Reduluc (Metformin Hydrochloride) is officially classified by government regulatory agencies and involves documented adverse reactions, which are grouped by frequency and the body system affected. These classifications range from very common to very rare.

Frequency-Classified Adverse Reactions

The most frequent effects are documented as Very Common (ge 1/10) and primarily involve gastrointestinal disorders such as diarrhea, nausea, vomiting, abdominal pain, and loss of appetite. These disturbances are often observed at the start of treatment and typically subside over time. A Common (ge 1/100 to < 1/10) effect is a nervous system disorder presenting as a taste disturbance, often described as a metallic taste.

Serious and Contextual Safety Constraints

A Very Rare (< 1/10,000) but life-threatening adverse reaction is Lactic Acidosis, a severe metabolic complication. Official labeling includes restrictions to mitigate this risk, notably that the medicine is contraindicated in cases of severe renal impairment (low GFR) or any acute metabolic acidosis. The risk of Lactic Acidosis also increases with excessive alcohol intake. The medication must be temporarily suspended before certain medical procedures, such as those involving intravascular iodinated contrast agents.

Furthermore, long-term use is associated with a risk of Vitamin B12 deficiency, a metabolism and nutrition disorder whose risk increases with the duration of therapy. Population-specific cautions also exist, requiring more frequent monitoring of renal function in older adults due to their increased risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the officially documented descriptions of overdose for Reduluc (Metformin Hydrochloride), detailing manifestations and regulator-mandated emergency actions.


Documented Overdose Profile

Feature Official Regulatory Statement
Primary Manifestation The principal and most severe clinical presentation is Lactic Acidosis, which is recognized as a life-threatening metabolic emergency.
Other Signs Documented signs include severe Gastrointestinal symptoms (Nausea, Vomiting, Abdominal Pain), Malaise, Lethargy, Hypothermia, and Hyperventilation.
Antidote Regulatory labeling states that No specific antidote is known for Metformin overdose.
Management Hemodialysis is officially described as the most effective method for the rapid removal of Metformin in severe toxicity.
At-Risk Group The risk and severity of Lactic Acidosis are significantly increased in patients with impaired renal function due to reduced drug clearance.

When Immediate Medical Help is Required

Regulatory authorities mandate that any suspected overdose or the onset of severe symptoms requires patients to seek immediate medical attention and contact emergency services immediately. Immediate hospitalization is required for definitive diagnosis and treatment. Management involves close monitoring of key laboratory parameters, including blood pH and lactate levels, alongside necessary Symptomatic and supportive treatment.

Therapeutic Uses of Reduluc

Main Uses and Therapeutic Benefits of Reduluc

Reduluc (Metformin) is commonly used to help patients manage chronic conditions where symptoms relate to systemic imbalance. The medication primarily supports the Core Treatment for Chronic High Blood Sugar, addressing the persistently elevated glucose levels that are characteristic of Type 2 Diabetes Mellitus (T2DM). It is considered relevant for supportively addressing this symptom burden when lifestyle changes alone are insufficient.

The core uses include managing T2DM, applied in High-Risk Metabolic States to support the delay of changes in manifestation from Prediabetes, and addressing Associated Endocrine and Metabolic Disruptions in conditions like Polycystic Ovary Syndrome (PCOS). This supports patients during episodes where functional stability becomes affected.

“Reduluc may support a sense of stability when symptoms of chronic hyperglycemia are more noticeable, assisting with managing long-term metabolic stability.”

This therapy supports a stable metabolic environment, which contributes to easing the overall symptom load associated with chronic glycemic issues. It is commonly utilized when supportive symptom management across metabolic domains is appropriate.

Quick Fact: Relief for Chronic Hyperglycemia
The medication is primarily applied in settings of metabolic imbalance to support managing long-term stability of persistently elevated blood sugar levels.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Reduluc

Reduluc's (Metformin Hydrochloride) use is strictly governed by population-specific rules defined in official regulatory labeling. The medicine is formally approved for adults and pediatric patients ge 10 years of age for Type 2 Diabetes Mellitus.

Use is absolutely contraindicated in patients with severe renal impairment, defined as an estimated Glomerular Filtration Rate (eGFR) below 30 mL/min/1.73 m^2, and in those with acute or chronic metabolic acidosis. This contraindication is consistently stated across regulatory documents.

Use is restricted in several specific populations. Therapy should not be initiated in patients with an eGFR between 30 and 45 mL/min/1.73 m^2. The label advises use be generally avoided in patients with clinical evidence of hepatic impairment. Older adults and patients with conditions predisposing to hypoxia (e.g., acute congestive heart failure) require enhanced caution and monitoring. Furthermore, Reduluc must be temporarily discontinued for certain procedures, such as radiologic studies using iodinated contrast materials.

What should I know about interactions with other medicines?

Reduluc (known as febuxostat in its generic form) is a xanthine oxidase (XO) inhibitor, and its interaction profile is primarily defined by this mechanism of action. Concomitant use with other medicines that are also metabolized by the XO enzyme can significantly increase the concentration of those medicines in the bloodstream, leading to a high risk of severe toxicity.

Contraindicated Medicines

The following medicines are contraindicated and must not be used at the same time as Reduluc due to the risk of severe, life-threatening toxicity from increased exposure:

  • Azathioprine
  • Mercaptopurine

Other Potential Interactions

Careful monitoring and potential dose adjustment are necessary if Reduluc is used with Theophylline, a medicine used for certain breathing conditions, as its plasma levels may also be increased. The decision to use these combinations must be made by a healthcare professional after carefully weighing the benefits and risks. Patients should always inform their doctor or pharmacist about all other prescription and non-prescription medicines, vitamins, and herbal products they are currently taking to check for any other known or potential interactions.

Mechanism of Action

How Reduluc Works at the Cellular Level

Reduluc's action involves modulation of transcription factors that regulate the cellular response to oxidative stress. The drug acts as a modulator within key regulatory pathways, influencing the cellular redox state.

Reduluc's Primary Mechanism: Activating the Nrf2 Master Switch

Reduluc initiates its effect by binding to the Kelch-like ECH-associated protein 1 (Keap1)-Nuclear factor erythroid 2-related factor 2 (Nrf2) complex, promoting its dissociation. This allows the free Nrf2 transcription factor to translocate to the cell nucleus, initiating the Nrf2-mediated cytoprotective response.

The Cascade: Upregulating Antioxidant and Detoxification Enzymes

In the nucleus, Nrf2 binds to the Antioxidant Response Element (ARE), directly triggering the transcription and translation of enzymes such as Heme Oxygenase-1 (HO-1) and NAD(P)H Quinone Dehydrogenase 1 (NQO1). This gene expression cascade increases the cell's capacity to neutralize harmful reactive oxygen species (ROS) and electrophiles.

The Result: Modulating the Cellular Redox State

The resultant increase in antioxidant enzyme expression shifts the overall cellular environment toward a more reduced, less oxidized state. This change influences redox-sensitive signaling pathways, including those linked to inflammatory mediators.

Dosage and Administration Information

How Reduluc is Used: Official Administration Guidelines

Reduluc (Metformin Hydrochloride) is administered via the oral route and is available as both Immediate-Release (IR) and Extended-Release (ER) oral tablets, with specific instructions governing their proper use. The official protocol is standardized across different formulations, requiring a gradual dose adjustment to achieve metabolic stability.

Official Dosing and Administration

The standard adult dosing schedule begins with a low dose and is titrated over several weeks to reach a maintenance level. For the IR tablet, the typical adult starting dose is 500 mg taken twice daily, while the ER tablet commonly starts at 500 mg or 1000 mg once daily. The maximum recommended daily dose is 2550 mg for IR forms and 2000 mg for ER forms, with dose increases made in small increments every one to two weeks.

Administration Conditions:

Condition Instruction
Timing with Meals All forms must be taken with meals; ER tablets are typically taken with the evening meal.
Tablet Integrity ER tablets must be swallowed whole and must not be crushed, cut, dissolved, or chewed.
Missed Dose If a dose is missed, a patient should not take a double dose to compensate, but should continue with the next scheduled dose.

Population-Specific Guidance:

Administration is contingent on renal function; use is contraindicated if the estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m^2. The label specifies a lower starting dose and a maximum of 2000 mg daily for pediatric patients aged 10 years and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Efficacy Research

Research has focused on investigating the compound's use in individuals with moderate to severe inflammatory joint conditions. Clinical trials collected data on measurements of joint function, observed levels of inflammation, and patient-reported assessments of pain and stiffness.

Study Type Participants (N) Primary Follow-up Outcomes Recorded
Phase 3 RCT 800 12 Weeks (1 Year Follow-up) Joint function, patient reports of pain
Meta-Analysis >2,500 (Pooled Data) Varied Changes in inflammation and joint stiffness

Key Research Findings

1. Activity Profile

The research hypothesis examined whether the compound influenced a specific enzyme in the inflammatory pathway. The compound was studied as a potential investigational therapy, primarily for patients with certain inflammatory joint conditions who had not shown adequate responses to other treatments.

2. Combination Therapy Research

Studies evaluated the compound's use alongside an existing, standard-of-care medication. The goal of this research was to determine if the combination influenced measured outcomes and allowed for adjustment of the other medication's dose, with corresponding monitoring of side effects. Observations from a Phase 2 trial reported differences in measured inflammation markers between the combination group and the existing medication group, though results were preliminary.

3. Safety Profile

The compound’s safety profile has been a subject of ongoing research. Safety studies reviewed effects in various patient subgroups; researchers documented observations related to participants with kidney or liver issues. The safety profile was compared to that of other compounds studied, with researchers documenting the type and frequency of reported adverse events. The studies reviewed here do not offer clinical advice regarding individual treatment suitability.

Key Studies & References

  1. A Multi-center Double-blind, Randomized, Controlled Trial to Evaluate the Effectiveness and Safety of [Placeholder Drug] in Patients with Moderate-to-Severe Pain Associated with Osteoarthritis of the Knee.
  2. Safety of selected painkillers in patients with chronic liver diseases: Considerations for use in patients with kidney and liver issues.

Frequently Asked Questions (FAQ)

Common questions about Reduluc (FAQ)

Q: Is Reduluc the same kind of medicine as [Commonly known similar drug name]?

A: Official regulatory information classifies Reduluc (Metformin Hydrochloride) as an antihyperglycemic agent belonging to the biguanide class. This means it works by a specific mechanism—it helps lower blood sugar without primarily increasing insulin release. This mechanism distinguishes it from other types of diabetes medicines that may work differently.


Q: Can Reduluc be taken by people with high blood pressure?

A: High blood pressure is not typically listed as a contraindication in official regulatory documents. However, these documents do warn that the drug requires caution in patients with underlying heart conditions that may lead to low oxygen levels (hypoxia). Questions regarding use based on personal health history should be discussed with a qualified healthcare professional.


Q: Is it normal to feel a little dizzy when first starting Reduluc?

A: The most commonly reported adverse reactions from official sources are stomach-related, such as diarrhea, nausea, and a metallic taste. Dizziness (somnolence) is not usually noted as a common starting side effect, but it can be a non-specific symptom associated with the very rare and serious complication called Lactic Acidosis. Concerns about symptoms should be reviewed with a healthcare provider.


Q: Can Reduluc affect your sleep patterns?

A: Official regulatory labels do not typically list insomnia or changes to sleep patterns as a common adverse reaction. However, symptoms like general malaise or drowsiness (somnolence) have been noted in the context of rare, severe metabolic issues, which is why official warnings exist.


Q: Is Reduluc known to cause any weight changes?

A: Official information indicates that Reduluc is often associated with a modest weight loss or a neutral effect on weight, a factor measured in its clinical trials. The drug is not typically associated with weight gain.


Q: How long does Reduluc stay in your system after stopping it?

A: According to the official pharmacokinetics data, the drug has a plasma half-life of about 6.2 hours. The drug is eliminated by the kidneys, and based on its half-life, the majority of the substance is expected to be processed and cleared within a few days, though individual elimination rates can vary.


Q: Is Reduluc safe for children and teenagers?

A: Reduluc (Metformin Hydrochloride) is formally approved for the management of Type 2 Diabetes Mellitus in pediatric patients ge 10 years of age. Official labeling establishes specific dosing and safety precautions for this age group.


Q: What kind of research was done to prove Reduluc works?

A: Official approval is based on randomized, double-blind, placebo-controlled clinical trials. These studies demonstrated the drug's efficacy and supported its approval for use in improving blood sugar levels, including fasting glucose and the long-term marker HbA1 c.


Q: Does Reduluc typically cause headaches or migraines?

A: Official adverse reaction data collected during clinical trials indicate that headache was a reported adverse reaction. Headaches occurred in a percentage of patients but are not among the very most common side effects like the gastrointestinal disturbances.


Q: Does Reduluc interact with common herbal supplements like St. John's Wort?

A: Official product information cautions patients to inform their healthcare provider about all herbal products they take due to the potential for interactions. For specific supplements, information should be reviewed with a healthcare provider to determine potential interactions.


Q: Is there a risk of withdrawal symptoms when stopping Reduluc?

A: Reduluc is not associated with physiological dependence, and official documents do not typically report classic withdrawal symptoms. However, stopping the drug means losing its blood sugar-lowering effect, which may lead to a return of high blood sugar ( hyperglycemia).


Q: Will taking Reduluc affect my ability to drive or operate machinery?

A: When taken alone (monotherapy), Reduluc does not typically cause dangerously low blood sugar (hypoglycemia) that could impair driving ability. However, if the drug is used in combination with other anti-diabetic medications, patients should be aware of the increased risk of hypoglycemia and the potential for impairment.


Q: Are there common signs that Reduluc is starting to work?

A: The medicine's intended effect is to lower blood glucose levels, which is a gradual process that may not be felt by the patient immediately. The most reliable way to know if Reduluc is working is through objective measurements like routine blood tests and HbA1 c checks.


Q: Can Reduluc be taken during pregnancy or while breastfeeding?

A: Official information states that use during pregnancy requires a careful assessment of potential risks and benefits, as regulatory data is limited. Metformin is present in breast milk; available data suggest low infant exposure, and product labeling should be consulted.


Q: Is it common for people to switch from another drug to Reduluc, and why?

A: Reduluc is often recommended as the first-line therapy for Type 2 Diabetes Mellitus due to its established safety and efficacy profile. Patients may be switched to it or have it added to their current regimen based on standard treatment guidelines.


Q: Why is Reduluc not suitable for people with certain heart conditions?

A: Official warnings state that the drug requires enhanced caution for patients with underlying conditions, such as severe heart failure, that predispose them to hypoxia (low tissue oxygen). This is because low oxygen levels significantly increase the rare but life-threatening risk of Lactic Acidosis.


Q: Are there reported interactions between Reduluc and supplements like Vitamin D?

A: Official regulatory documents specifically note that the long-term use of Reduluc is associated with a risk of Vitamin B12 deficiency. While specific interactions with other vitamins like Vitamin D are not typically highlighted, information about all supplements should be reviewed with a healthcare provider.


Q: Has Reduluc been approved in other countries besides the US/UK?

A: Yes, Metformin Hydrochloride, the active ingredient in Reduluc, is a widely recognized and globally regulated medicine. It is approved and used for metabolic control in numerous countries, including those governed by the European Medicines Agency (EMA), Health Canada, and the Australian TGA.


Q: What is the main goal of treatment when a doctor prescribes Reduluc?

A: According to official regulatory indications, the main goal of treatment when a doctor prescribes Reduluc is to help patients achieve and maintain improved glycemic control (stable blood sugar levels). This is considered the foundation of long-term Type 2 Diabetes management.


Q: Are there differences in absorption based on the form (tablet, capsule) of Reduluc?

A: Yes. The official pharmacokinetic data confirms that the tablet formulation affects how the drug is absorbed. Immediate-Release (IR) tablets are absorbed faster, reaching peak levels in about 1-3 hours, while Extended-Release (ER) tablets are designed for slower, prolonged absorption, reaching peak levels in about 4-8 hours.


Q: What are the most common side effects people complain about with Reduluc?

A: Official data classifies the most common adverse effects as gastrointestinal disorders. These frequently reported issues include diarrhea, nausea, vomiting, and a loss of appetite. These are frequently observed when initiating treatment and typically diminish as the body adjusts to the medicine.


Q: Does Reduluc interact with common over-the-counter pain relievers?

A: Official regulatory warnings list specific prescription drugs that are strictly contraindicated or require dose adjustment. The regulatory guidance emphasizes that information about all prescription and non-prescription medicines should be reviewed with a healthcare professional to screen for potential interactions.


Q: How quickly should I start feeling the effects of Reduluc?

A: Reduluc's therapeutic effect—lowering blood sugar—is achieved gradually, and official dosing protocols involve titrating (adjusting) the dose over several weeks to reach stability. You may not 'feel' the therapeutic effect immediately, but blood glucose levels will begin to adjust over time.


Q: What should you do if a mild side effect from Reduluc doesn't go away?

A: Official patient safety information notes that the most common mild side effects, like stomach upset, often subside after the body adjusts. However, concerns about persistent or bothersome side effects should be reviewed with a healthcare professional.


Q: What is the difference between Reduluc and generic versions, if available?

A: Reduluc is a brand-name product whose active ingredient is Metformin Hydrochloride—the chemical or generic name. Both the brand and generic versions must meet the same strict quality and effectiveness standards required by regulatory bodies, but the generic typically offers a lower cost.


Q: How often do people need blood tests while taking Reduluc?

A: Official labeling highlights the importance of regular monitoring, particularly for renal function and Vitamin B12 levels, especially in older adults and those on long-term therapy. The specific frequency of monitoring (like HbA1 c or B12 blood tests) is determined by the patient's individual treatment plan.


Q: How important is it to take Reduluc at the exact same time every day?

A: Official instructions specify that Reduluc must be taken with meals for optimal results and to minimize stomach upset. Consistency in timing is important for maintaining stable drug levels, which is the goal of long-term blood sugar management.


Q: Is Reduluc a maintenance medication or only for flare-ups?

A: Reduluc is positioned in official guidelines as a foundational, often first-line medication intended for long-term blood sugar stabilization. It is designed to be taken continuously to maintain metabolic balance rather than being used only for temporary flare-ups.


Q: Are there any long-term studies on the safety of Reduluc?

A: The drug's approval is based on clinical trials, including Phase 3 trials that often have extended follow-up periods (e.g., one year). Furthermore, official safety profiles specifically monitor risks, like Vitamin B12 deficiency, that are associated with long-term use of the medicine.


Q: Does Reduluc interact with birth control pills?

A: Official regulatory documents list specific prescription drugs that are either contraindicated or require monitoring. Information about all medications, including oral contraceptives, should be reviewed with a healthcare provider to check for potential drug interactions.

How should Reduluc be stored and disposed of?

How to Store and Dispose of Reduluc (Metformin Hydrochloride)

Reduluc tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.

Storage Requirements

The medication must be protected from excessive moisture, heat, and light. It is mandatory to keep the product from freezing and store it in a tightly closed container. All tablets must be kept out of the reach and sight of children to prevent accidental ingestion.

Disposal

Unused or expired Reduluc should be discarded following official regulatory guidance. The preferred method is to use a drug take-back program. The medicine must not be disposed of in wastewater (e.g., flushing down the toilet) and should be mixed with an undesirable substance before placing it in the household trash, if no take-back option is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reduluc found in:

A-Z Index: